Literature DB >> 1980383

Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice.

J C Cal1, P T Daley-Yates.   

Abstract

The purpose of this study was to investigate the disposition and the nephrotoxicity of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD-pamidronate) in order to elucidate the mechanism of the non-linearity of the renal elimination of this drug. The fate of APD labelled with [14C]APD was studied in mice and rats for a range of doses (0.5-40 mg/kg) and indicators of renal function were monitored. In both species, the percentage of dose excreted during the first 24-h after treatment fell dramatically as a function of the dose. However, the renal burden of APD rose linearly for doses of APD below 10 mg/kg and increased non-linearly over this threshold. In contrast the concentration of APD in both bone and liver, which together account for a large proportion of the dose, appeared to increase proportionally with dose. There was no evidence, therefore, that the non-linear renal elimination of APD was due to an increased uptake of APD by tissues. Conversely, the significant fall in the renal excretion of APD was paralleled by a striking loss in body weight, and for high doses, by a fall in the creatinine clearance. An increased enzymuria suggested the loss of brush border membranes and the release of lysosomal contents by proximal tubular cells. Morphological studies confirmed this and revealed a focal proximal tubular necrosis 6 days post dosing. We conclude that the nephrotoxicity of APD accounts for the non-linear renal elimination of this drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980383     DOI: 10.1016/0300-483x(90)90088-x

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  6 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Measurement of serum [3H]tetracycline kinetics and indices of kidney function facilitate study of the activity and toxic effects of bisphosphonates in bone resorption.

Authors:  G Golomb; Y Eitan; A Hoffman
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

3.  Acute kidney injury and bisphosphonate use in cancer: a report from the research on adverse drug events and reports (RADAR) project.

Authors:  Beatrice J Edwards; Sarah Usmani; Dennis W Raisch; June M McKoy; Athena T Samaras; Steven M Belknap; Steven M Trifilio; Allison Hahr; Andrew D Bunta; Ali Abu-Alfa; Craig B Langman; Steve T Rosen; Dennis P West
Journal:  J Oncol Pract       Date:  2013-03       Impact factor: 3.840

4.  The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse.

Authors:  C R Hoggarth; R Bennett; P T Daley-Yates
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

5.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

6.  The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: a light and electron microscopy study.

Authors:  İbrahim Unal Sert; Ozcan Kilic; Murat Akand; Lutfi Saglik; Mustafa Cihat Avunduk; Esra Erdemli
Journal:  Arch Med Sci       Date:  2016-05-30       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.